(Q36044597)

11 August 2017

title

Obesity in schizophrenia: what can be done about it? (English)

1 reference

11 August 2017

0 references

1 reference

Lisa Catapano

1

1 reference

11 August 2017

David Castle

series ordinal

2

1 reference

11 August 2017

publication date

1 March 2004

1 reference

11 August 2017

published in

Australasian Psychiatry

1 reference

11 August 2017

volume

12

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

23-25

1 reference

Atypical antipsychotics and weight gain--a systematic review

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Understanding the new and evolving profile of adverse drug effects in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Detection and management of comorbidity in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Body mass index and quality of life in community-dwelling patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

The impact of weight gain on quality of life among persons with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

A program for treating olanzapine-related weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Clozapine-induced weight gain predicts improvement in psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1039-8562.2003.02054.X

10.1046/J.1039-8562.2003.02054.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference